December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Efficacy and Safety of Switching to Latanoprost 0.005% from Other Monotherapy Treatment
Author Affiliations & Notes
  • TJ Zimmerman
    Ophthalmology University Louisville Louisville KY
  • Footnotes
    Commercial Relationships    T.J. Zimmerman, Pharmacia Corp. E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1086. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      TJ Zimmerman; Efficacy and Safety of Switching to Latanoprost 0.005% from Other Monotherapy Treatment . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1086.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the efficacy and safety of latanoprost 0.005% after switching from previous monotherapy. Method: In this multicenter, prospective, open label study we enrolled primary open-angle glaucoma or ocular hypertension patients switched from previous monotherapy (at least one week of treatment) to latanoprost for reasons of either: improved intraocular pressure (IOP) control, adverse event, non-compliance, cost or convenience. Patients were followed for three months. Results: In all 149 patients the average IOP after switching to latanoprost changed from 19.6 3.4 on previous therapy to 16.7 3.5 mm Hg. For those patients with uncontrolled IOP (n = 99) the average pressure after switching to latanoprost fell from 20.5 3.7 to 17.2 3.8 mm Hg. For those switched to latanoprost for non-IOP related reasons (n = 50), including an adverse event and non-compliance, the average IOP changed from 17.8 3.3 to 15.7 3.5 mm Hg. Specific medicines changed to latanoprost are listed in the table. Table (mm Hg ± SD)  

For patients switched to latanoprost for better pressure control 87% (n = 86) had at least ≥ 1 mm Hg further reduction in IOP. For patients switched for an ocular adverse event (non-IOP reason) (n = 31),100 % had resolution of the adverse event and without a ≥ 2 mm Hg increase in IOP. For those switched for non-compliance (n = 19) 79 % (n = 15) of patients demonstrated ≥ 1 mm Hg further reduction in IOP, possibly indicating greater compliance or efficacy with latanoprost. No patients were discontinued for an adverse event after switching to latanoprost. Conclusion: Latanoprost may be successfully switched to from a variety of other monotherapy medicines without incurring discontinuation from an adverse event and maintaining at least similar IOP control.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 354 clinical (human) or epidemiologic studies: prevalence/incidence • 353 clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.